ALDX Stock Risk & Deep Value Analysis
Aldeyra Therapeutics Inc
DVR Score
out of 10
What You Need to Know About ALDX Stock
We analyzed Aldeyra Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ALDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ALDX Risk Analysis & Red Flags
What Could Go Wrong
The ongoing class-action lawsuits could result in substantial financial penalties and legal fees, draining Aldeyra's limited cash reserves. Combined with continued R&D expenses and no revenue, this could force highly dilutive capital raises or even lead to insolvency within the next 12-18 months.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Third Complete Response Letter (CRL) from FDA for reproxalap in dry eye disease, 'effectively eliminating' its primary market opportunity.
- ⚠
Ongoing securities class-action lawsuits alleging misleading disclosures.
- ⚠
Significant 70.7% stock drop on March 17, 2026, post-CRL.
- ⚠
Pre-revenue company with high cash burn and uncertain funding pathway.
- ⚠
Resignation of Chief Development Officer prior to previous analysis.
Upcoming Risk Events
- 📅
Unfavorable outcome or settlement in securities class-action lawsuit
- 📅
Further regulatory setbacks for reproxalap or other pipeline candidates
- 📅
Significant cash crunch necessitating highly dilutive financing
When to Reconsider
- 🚪
Further negative regulatory news for reproxalap or other pipeline assets.
- 🚪
Announcement of a highly dilutive capital raise (e.g., >20% dilution).
- 🚪
Cash and equivalents dropping below $50 million, signaling short runway.
- 🚪
Unfavorable ruling or significant settlement in the class-action lawsuit.
Unlock ALDX Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Aldeyra Therapeutics presents an extremely high-risk, low-reward speculative opportunity. Any investment would be a contrarian bet on an improbable reversal of regulatory fortunes for reproxalap (despite multiple CRLs) or the rapid, successful advancement of its nascent pipeline, while simultaneously navigating severe legal and financial distress. The path to 10x growth within 3-5 years is virtually nonexistent from the current vantage point.
Is ALDX Stock Undervalued?
Unlock the full AI analysis for ALDX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ALDX Price Targets & Strategy
12-Month Target
$0.50
Bull Case
$5.00
Bear Case
$0.25
Valuation Basis
Based on an estimated discounted net asset value reflecting projected cash burn of $20M/quarter and an estimated $50M in legal liabilities over 12 months.
Entry Strategy
Avoidance is recommended due to extreme risk. For highly speculative investors, dollar-cost average below current distressed levels ($1.50 or lower) with very small allocation.
Exit Strategy
For speculative positions, take any profit above $2.50. Implement a strict stop-loss below $1.00.
Portfolio Allocation
0% for conservative/moderate portfolios; <0.5% for highly aggressive, speculative portfolios.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is ALDX Financially Healthy?
Valuation
P/E Ratio
-2.00
Forward P/E
-2.70
PEG Ratio
0.03
Price/Book
1.60
Price/Sales
12.00
Profitability
Return on Equity
-63.75%
EPS
$-0.56
Balance Sheet
Current Ratio
2.58
Quick Ratio
2.56
Debt/Equity
0.34
Other
Beta (Volatility)
1.19
Does ALDX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
The intellectual property for reproxalap has been severely diminished in value by multiple regulatory rejections and legal challenges, making its durability extremely low without an unexpected and dramatic turnaround. Other pipeline assets are too early to establish a significant moat.
Moat Erosion Risks
- •Failure to achieve regulatory approval for any pipeline asset.
- •Invalidation or circumvention of existing patents.
- •Successful development and commercialization of competing therapies.
ALDX Competitive Moat Analysis
Sign up to see competitive advantages
ALDX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish, reflecting the substantial stock price decline and ongoing legal/regulatory issues.
Institutional Sentiment
Negative, indicated by previous substantial institutional ownership drop and the current lack of reported analyst upgrades or price targets.
Insider Activity (Form 4)
No Form 4 filings (insider buys/sells) reported in the last 90 days (Mar 12–May 10, 2026).
Options Flow
Normal options activity (no specific unusual activity reported in research).
Earnings Intelligence
Next Earnings
Estimated May 13, 2026 after market close
Surprise Probability
Low, as a pre-revenue biotech, focus will be on cash burn and pipeline updates rather than EPS beats/misses which are less meaningful.
Historical Earnings Pattern
Highly volatile, with significant reactions to regulatory news (e.g., 70%+ drop on CRL). Earnings for pre-revenue biotechs typically have muted impact unless accompanied by major pipeline news.
Key Metrics to Watch
Competitive Position
Top Competitor
No direct 'best-in-class' competitor named from the provided data; the company is specialized in inflammatory/immune diseases, but its lead dry eye asset has failed regulatory hurdles. Competitors would be companies with approved dry eye treatments.
Market Share Trend
Losing ground; unable to enter the market with its lead product.
Valuation vs Peers
Valuation is distressed and not comparable with revenue-generating peers; trades at a significant discount even to other early-stage biotechs due to regulatory failures and legal issues.
Competitive Advantages
- •Proprietary compound (reproxalap), but regulatory failure diminishes its value.
- •Pipeline of other early-stage candidates targeting inflammatory diseases.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive ALDX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Reported May 7, 2026)
- •Next Earnings estimated May 13, 2026
- •Lead plaintiff deadline for securities lawsuit May 29, 2026 (Negative)
- •PDUFA extension outcome for reproxalap NDA (Highly uncertain)
Medium-Term (6-18 months)
- •Updates on other pipeline assets (e.g., ADX-2191 for RVO, ADX-622 for psoriasis/atopic dermatitis, though less prominent)
- •Potential (unlikely) favorable resolution of legal challenges
Long-Term (18+ months)
- •Unlikely successful commercialization of reproxalap in any indication
- •Development of a new lead asset with strong clinical data and regulatory path
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for ALDX?
- ✓
A clear, unexpected FDA approval for reproxalap (highly unlikely).
- ✓
Positive and definitive resolution of the securities class-action lawsuits.
- ✓
Significant clinical data milestones for non-reproxalap pipeline assets (e.g., ADX-2191, ADX-622).
- ✓
New leadership with a strong, proven track record.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Aldeyra Therapeutics Inc Makes Money
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for inflammatory, autoimmune, and metabolic diseases. Its business model relies on identifying and developing drug candidates through clinical trials, with the ultimate goal of obtaining regulatory approval from agencies like the FDA. Once approved, the company would generate revenue through direct commercialization of its products or through licensing agreements with larger pharmaceutical partners. Currently, it operates as a research and development entity with no commercial products, primarily burning cash to fund its drug discovery and clinical development efforts.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Aldeyra Therapeutics Inc (ALDX)?
As of May 10, 2026, Aldeyra Therapeutics Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Aldeyra Therapeutics Inc?
Aldeyra Therapeutics Inc's market capitalization is approximately $104.4M..
What is the risk level for ALDX stock?
Our analysis rates Aldeyra Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ALDX?
Aldeyra Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -2.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the ALDX DVR analysis updated?
Our AI-powered analysis of Aldeyra Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 10, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ALDX (Aldeyra Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.